StockpollyBeta
Get App
Delisting riskPopularity #3,258
HUMA · NASDAQ · Biotechnology

Humacyte (HUMA)

Commercializing Symvess while expanding its ATEV vessel platform.

$0.5900
After-hours close+0.01 (+1.18%)
At close$0.5831(−1.17%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000007101000
Cost of revenue1322242221121
Gross profit−1−3−2−2−24−1−2−1−10−2−1
232325282832222823202726
Research & development192021242321152217151918
6344711886688
Selling & marketing00−2−204000000
General & administrative605677880088
Other expenses−1000−20−2−20000
Operating income−25−26−27−29−30−28−23−30−24−31−29−27
−11−5−27−9762−87611−10
Interest income111111111100
Interest expense122323333322
Other non-operating income0−34257−10−655−9−9−147
Income before tax−26−25−32−57−39−2139−38−18−25−18−37
Net income from continuing operations−26−25−32−57−39−2139−38−18−25−18−37
Net income−26−25−32−57−39−2139−38−18−25−18−37
EPS, basic−$0.25−$0.24−$0.29−$0.48−$0.33−$0.16$0.28−$0.24−$0.11−$0.15−$0.09−$0.16
EPS, diluted−$0.25−$0.24−$0.29−$0.48−$0.33−$0.16$0.28−$0.24−$0.11−$0.15−$0.09−$0.16
Weighted average shares, basic103104108119119118131155158158198234
Weighted average shares, diluted103104108119119118132155158158198234
EBITDA−23−20−28−52−35−1744−33−13−20−14−33
Depreciation & amortization132222222221
EBIT−25−23−30−54−37−1842−35−15−22−15−34